Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | LEADER: Biomarker analyses of lenvatinib plus eribulin for sarcoma

Tom Wei-Wu Chen • 11 Sep 2022
ESMO 2022
Sarcoma Eribulin Lenvatinib
LEADER

Tom Wei-Wu Chen, MD, National Taiwan University Hospital, Taipei, Taiwan, discusses biomarker analyses from the Phase I/II LEADER trial (NCT03526679), which investigated lenvatinib plus eribulin for patients with leiomyosarcoma and liposarcoma. The results of these analyses suggest a possible immunotherapeutic and vascular effect of this combination therapy for these patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tom Wei-Wu Chen

1:36
DeFi: nirogacestat demonstrates improved PFS and ORR in progressing desmoid tumors
Tom Wei-Wu Chen • 11 Sep 2022
1:41
Differences in soft tissue sarcoma incidences and clinical characteristics between France and Taiwan
Tom Wei-Wu Chen • 11 Sep 2022
1:26
Next steps for LEADER trial: lenvatinib plus eribulin for sarcoma
Tom Wei-Wu Chen • 11 Sep 2022

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals